Adam R. Craig - 29 Dec 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
President and CEO, Director
Signature
Adam R. Craig
Issuer symbol
N/A
Transactions as of
29 Dec 2022
Net transactions value
-$589,389
Form type
4
Filing time
03 Jan 2023, 18:47:50 UTC
Previous filing
14 Nov 2022
Next filing
26 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $11,607 +13,800 +50% $0.8411* 41,661 29 Dec 2022 Direct
transaction CTIC common stock Sale $82,800 -13,800 -33% $6.00 27,861 29 Dec 2022 Direct F1
transaction CTIC common stock Award $8,066 +1,579 +5.7% $5.11 29,440 30 Dec 2022 Direct F2
transaction CTIC common stock Options Exercise $10,093 +12,000 +41% $0.8411* 41,440 30 Dec 2022 Direct
transaction CTIC common stock Sale $72,000 -12,000 -29% $6.00 29,440 30 Dec 2022 Direct F1
transaction CTIC common stock Options Exercise $589 +700 +2.4% $0.8411* 30,140 30 Dec 2022 Direct
transaction CTIC common stock Sale $4,204 -700 -2.3% $6.00 29,440 30 Dec 2022 Direct F1
transaction CTIC common stock Options Exercise $3,701 +4,400 +15% $0.8411* 33,840 30 Dec 2022 Direct
transaction CTIC common stock Sale $26,444 -4,400 -13% $6.01 29,440 30 Dec 2022 Direct F1
transaction CTIC common stock Options Exercise $71,227 +84,683 +288% $0.8411* 114,123 03 Jan 2023 Direct
transaction CTIC common stock Sale $509,224 -84,683 -74% $6.01 29,440 03 Jan 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -13,800 -2.1% $0.000000 657,154 29 Dec 2022 Common Stock 13,800 $0.8411 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -12,000 -1.8% $0.000000 645,154 30 Dec 2022 Common Stock 12,000 $0.8411 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -700 -0.11% $0.000000 644,454 30 Dec 2022 Common Stock 700 $0.8411 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -4,400 -0.68% $0.000000 640,054 30 Dec 2022 Common Stock 4,400 $0.8411 Direct F4
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -84,683 -13% $0.000000 555,371 03 Jan 2023 Common Stock 84,683 $0.8411 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F4 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.